• Duration of response [ Designated as safety issue: No ]
• Toxicity [ Designated as safety issue: Yes ]

• Duration of response
• Toxicity

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of carboplatin combined with paclitaxel in treating patients who have advanced thymoma.

OBJECTIVES:

• Determine the objective response rate in patients with advanced thymoma or thymic carcinoma treated with carboplatin and paclitaxel.
• Determine the duration of response in these patients treated with this regimen.
• Determine the toxicity of this regimen in these patients.

OUTLINE: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression. Patients achieving complete or partial remission or stable disease receive 4 additional courses of therapy for a maximum of 6 courses. Further treatment may be given at the discretion of the treating physician.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 35-68 patients will be accrued for this study within 3.8-4.6 years.

• Drug: carboplatin
• Drug: paclitaxel

DISEASE CHARACTERISTICS:

• Histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery

  • Extensive disease (distant disease, pleural disease, pulmonary with or without mediastinal disease, or recurrent progressive disease in site of prior radiotherapy)
  • Advanced limited disease allowed if ineligible for primary radiotherapy or surgery
• Measurable disease

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-1

Life expectancy:

• Not specified

Hematopoietic:

• Granulocyte count at least 1,500 cells/mm^3
• Platelet count at least 100,000 cells/mm^3

Hepatic:

• Bilirubin no greater than 1.5 mg/dL

Renal:

• Creatinine no greater than 2.0 mg/dL

Other:

• No acute concurrent complications such as infection or post-surgical complications
• No other prior malignancy within the past 5 years unless curatively treated with no evidence of recurrence
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for metastatic disease
• Prior preoperative or adjuvant chemotherapy allowed if disease-free survival prior to recurrence was more than 1 year

Endocrine therapy:

• Concurrent corticosteroids for myasthenia gravis or other chronic conditions allowed

Radiotherapy:

• See Disease Characteristics
• No concurrent local radiotherapy for pain control or life threatening situations

Surgery:

• See Disease Characteristics